COVID Antiviral Pill
Merck says it has first antiviral pill found to be effective against COVID
Molnupiravir is an experimental antiviral drug which is orally active and was developed for the treatment of influenza. It is a prodrug of the synthetic nucleoside derivative N4-hydroxycytidine, and exerts its antiviral action through introduction of copying errors during viral RNA replication.
Drugmaker Merck said Friday that its pill to treat COVID-19 was shown in a key clinical trial to halve the risk of hospitalization or death when given to high-risk people early in their infections.
In a potential leap forward in the global fight against the pandemic, drugmaker Merck said Friday that its experimental pill for people sick with COVID-19 reduced hospitalizations and deaths by half.
If cleared by regulators, it would be the first pill shown to treat COVID-19, adding a whole new, easy-to-use weapon to an arsenal that already includes the vaccine.
The company said it will soon ask health officials in the U.S. and around the world to authorize the pill’s use. A decision from the U.S. Food and Drug Administration could come within weeks after that, and the drug, if it gets the OK, could be distributed quickly soon afterward.
The strong results suggest that a new wave of effective and easy-to-use treatments for COVID will gradually become available in the United States, though supply is likely to be limited at first. Merck said it would seek emergency authorization from the Food and Drug Administration for its drug, known as molnupiravir, as soon as possible. The pills could be available by late this year.
Merck’s drug would be the first pill to treat COVID-19. It is likely to be followed by a number of other antiviral pills that other companies are racing to bring to market. They have the potential to reach more people than the antibody treatments that are being widely used in the United States for high-risk patients.
“I think it will translate into many thousands of lives being saved worldwide, where there’s less access to monoclonal antibodies, and in this country, too,” said Dr. Robert Shafer, an infectious disease specialist at Stanford University.
All other COVID-19 treatments now authorized in the U.S. require an IV or injection. A pill taken at home, by contrast, would ease pressure on hospitals and could also help curb outbreaks in poorer and more remote corners of the world that don’t have access to the more expensive infusion therapies.
“This would allow us to treat many more people much more quickly and, we trust, much less expensively,” said Dr. William Schaffner, an infectious disease expert at Vanderbilt University who was not involved in the research.
Merck and its partner Ridgeback Biotherapeutics said early results showed patients who received the drug, molnupiravir, within five days of COVID-19 symptoms had about half the rate of hospitalization and death as those who received a dummy pill.
The study tracked 775 adults with mild-to-moderate COVID-19 who were considered high risk for severe disease because of health problems such as obesity, diabetes or heart disease. The results have not been reviewed by outside experts, the usual procedure for vetting new medical research.
Among patients taking molnupiravir, 7.3% were either hospitalized or died at the end of 30 days, compared with 14.1% of those getting the dummy pill. After that time period, there were no deaths among those who received the drug, compared with eight in the placebo group, according to Merck.
The results were so strong that an independent group of medical experts monitoring the trial recommended stopping it early.
Company executives said they plan to submit the data to the FDA in the coming days.
Even with the news of a potentially effective new treatment, experts stressed the importance of vaccines for controlling the pandemic, given that they help prevent transmission and also reduce the severity of illness in those who do get infected.
White House officials Friday hailed the strong trial data, but they noted that the antiviral pills are no substitute for more Americans getting vaccinated. Despite the growing number of governments and companies mandating vaccines, only 56 percent of Americans are fully vaccinated.
“The right way to think about this is this is a potential additional tool in our toolbox to protect people from the worst outcomes of COVID,” said Jeff Zients, a White House coronavirus adviser. Vaccination, he said, “remains far and away our best tool against COVID-19. It can prevent you from getting COVID in the first place, and we want to prevent infections — not just treat them when they happen.”
The results of clinical trials of two other antiviral pills, one developed by Pfizer and the other from Atea Pharmaceuticals and Roche, are expected in the next few months.
The Merck drug — named for Mjölnir, the hammer wielded by thunder god Thor in Norse mythology — is designed to stop the coronavirus from replicating by inserting errors into its genetic code. Doctors will prescribe the treatment to patients, who will receive the pills from pharmacies. The drug is meant to be taken as four capsules twice a day for five days — a total of 40 pills over the course of treatment.
The federal government has placed advance orders for 1.7 million courses of treatment, at a price of about $700 per patient. That is about one-third of the current cost of a monoclonal antibody treatment, which is typically given to patients via intravenous hookups.
The limited number of doses that the US government has ordered means that only a small fraction of those who fall ill from COVID-19 are likely to be able to receive the treatment, at least initially. Merck said Friday that it expects to be able to make enough pills for 10 million people by the end of this year, though it is unclear how many of those doses will go to the United States or other countries.
COVID has killed nearly 700,000 Americans. Roughly half of those deaths occurred this year, even as vaccines became widely available.
Merck said an independent board of experts monitoring its clinical trial recommended that the trial be stopped early because the drug’s benefit to patients had proved so convincing. The company said the FDA had agreed with that decision.
The monitors looked at data through early August, when the study had enrolled 775 volunteers in the United States and overseas. Seven percent of those in the group that received the drug were hospitalized, and none died, compared with a 14 percent rate of hospitalization and death in the group that received placebo pills. Mild side effects, which can include headaches, were reported at the same rate in both groups.
The Merck pill appeared to be less effective than monoclonal antibody treatments, which have been in high demand recently. Studies have shown that they reduce hospitalizations and deaths by at least 70 percent in high-risk COVID patients. But the antibody treatments are expensive, are typically given intravenously, and are cumbersome for hospitals and clinics to administer.
Angela Rasmussen, a virus expert and research scientist at the Vaccine and Infectious Disease Organization at the University of Saskatchewan, said that antiviral pills could have a greater effect by virtue of reaching more people.
If the pills cut hospitalizations and deaths by half, “that is going to translate to an objectively larger number of lives saved potentially with this drug,” she said. “Maybe it isn’t doing the same numbers as the monoclonal antibodies, but it’s still going to be huge.”
Did you know that if you subscribe to our website, you will receive email notifications whenever content changes or new content is added.
1. Enter your e-mail address below and click the Sign Me Up button.
2. You will receive an email asking you to confirm your intention of subscribing to our site.
3. Click the link in the email to confirm. That’s all there is to it!
Then indicate you no longer wish to receive our emails.
Working Teddy Team